Monokine induced by interferon γ (IFNγ) (CXCL9) and IFNγ inducible T-cell α-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: Modulation by peroxisome proliferator-activated receptor-γ agonists

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 5, 2009, Pages 1803-1809

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Frascerra, Silvia ^a   Santini, Eleonora ^a   Franceschini, Stefano Sellari ^a   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; MONOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; ORBIT; PATHOGENESIS; PRIORITY JOURNAL; PROADIPOCYTE; T LYMPHOCYTE; TH1 CELL; THYROID CELL; ADIPOCYTE; BIOSYNTHESIS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; THYROID GLAND;

ADIPOCYTES; CELLS, CULTURED; CHEMOKINE CXCL11; CHEMOKINE CXCL9; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; HYPOGLYCEMIC AGENTS; INTERFERON-GAMMA; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66149120609     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2450     Document Type: Article

References (39)

1. Luster AD 1998 Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445
2. Mackay CR 1996 Chemokine receptors and T cell chemotaxis. J Exp Med 184:799-802 (Pubitemid 26313537)
3. Dewald B, Moser B, Barella L, Schumacher C, Baggiolini M, Clark-Lewis I 1992 IP-10, a γ-interferon-inducible protein related to interleukin-8, lacks neutrophil activating properties. Immunol Lett 32:81-84
4. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B 1996 Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963-969 (Pubitemid 26313554)
5. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ 1993 Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177:1809-1814
6. Mariotti S, Del Prete GF, Mastromauro C, De Carli M, Romagnani S, Ricci M, Pinchera A 1991 The autoimmune infiltrate of Basedow's disease: analysis of clonal level and comparison with Hashimoto's thyroiditis. Exp Clin Endocrinol 97:139-146
7. De Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, Del Prete G 1993 Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 77:1120-1124 (Pubitemid 23345455)
8. Aniszewski JP, Valyasevi RW, Bahn RS 2000 Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 85:776-780 (Pubitemid 32273668)
9. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF 2003 TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 58:280-287 (Pubitemid 36308115)
10. Heufelder AE, Smith TJ, Gorman CA, Bahn RS 1991 Increased induction of HLA-DR by interferon-γ in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy. J Clin Endocrinol Metab 73:307-313 (Pubitemid 21921874)
11. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21:168-199 (Pubitemid 32275594)
12. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 161:195-206 (Pubitemid 34760785)
13. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499 (Pubitemid 39518431)
14. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M 2005 Increase of interferon-γ inducible α chemokine CXCL10 but not β chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152:171-177 (Pubitemid 40309561)
15. Garcià-Lòpez MA, Sancho D, Sànchez-Madrid F, Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 86:5008-5016 (Pubitemid 33020557)
16. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 59:207-213 (Pubitemid 36918657)
17. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M 2006 Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 154:651-658 (Pubitemid 43810850)
18. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P 2006 Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93:1226-1231 (Pubitemid 44547021)
19. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E 2007 Iodine-131 given for therapeutic purposes modulates differently interferon-γ-inducible α-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 92:1485-1490 (Pubitemid 46556429)
20. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E 2006 Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J Clin Endocrinol Metab 91:614-620 (Pubitemid 43236933)
21. Mimura LY, Villares SM, Monteiro ML, Guazzelli IC, Bloise W 2003 Peroxisome proliferator-activated receptor-γ gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy. Thyroid 13:845-850 (Pubitemid 37222286)
22. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD 2000 Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164:6503-6508 (Pubitemid 30408835)
23. Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, Tonnel AB, Trottein F 2001 Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 31:2857-2865 (Pubitemid 32994536)
24. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ 2005 Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-γ ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 11:244-252 (Pubitemid 40439678)
25. Lehmann GM, Garcia-Bates TM, Smith TJ, Feldon SE, Phipps RP 2008 Regulation of lymphocyte function by PPARγ: relevance to thyroid eye disease-related inflammation. PPAR Res 2008:895901
26. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS 2002 Stimulation of adipogenesis, peroxisome proliferator-activated receptor-γ (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 87:2352-2358 (Pubitemid 34521530)
27. Bahn RS, Gorman CA, Johnson CM, Smith TJ 1989 Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein. J Clin Endocrinol Metab 69:622-662
28. Watson PF, Pickerill AP, Davies R, Weetman AP 1994 Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab 79:355-360 (Pubitemid 24256517)
29. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y 2000 Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 85:1194-1199 (Pubitemid 32269371)
30. Schulthess FT, Paroni F, Sauter NS, Shu L, Ribaux P, Haataja L, Strieter RM, Oberholzer J, King CC, Maedler K 2009 CXCL10 impairs β cell function and viability in diabetes through TLR4 signaling. Cell Metab 9:125-139
31. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD 1999 A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389 (Pubitemid 29534322)
32. Yang XY, Wang LH, Farrar WL 2008 A role for PPARγ in the regulation of cytokines in immune cells and cancer. PPAR Res 2008:961753
33. Crescioli C, Cosmi L, Borgogni E, Santarlasci V, Gelmini S, Sottili M, Sarchielli E, Mazzinghi B, Francalanci M, Pezzatini A, Perigli G, Vannelli GB, Annunziato F, Serio M 2007 Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 195:145-155 (Pubitemid 350056008)
34. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M, Galli A, Serio M, Luconi M 2008 A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-α and interferon-γ inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol 28:718-724
35. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A 2002 Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385-392 (Pubitemid 34084719)
36. Starkey K, Heufelder A, Bakerm G, Joba W, Evans M, Davies S, Ludgate M 2003 Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 88:55-59
37. Lee S, Tsirbas A, Goldberg RA, McCann JD 2007 Thiazolidinedione induced thyroid associated orbitopathy. BMC Ophthalmol 7:8 (Pubitemid 46791239)
38. Kumar S, Coenen MJ, Scherer PE, Bahn RS 2004 Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 89:930-935 (Pubitemid 38269913)
39. Feldon SE, O'loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP 2006 Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol 169:1183-1193